Altogether, we provide compelling evidence that DHEA is a potential therapeutic candidate for CRC patient treatment regardless of the p53 status through ER stress-PERK-autophagy-apoptosis axis. This evidence concerns the gene EIF2AK3 and colorectal carcinoma.